摘要
减少淀粉样-β(Aβ)的积累是治疗阿尔茨海默病(AD)疗法的一种很有发展前景的方法。我们最近报道了一种三苯甲烷食物染料模拟物,亮蓝G(BBG),是细胞实验中体外淀粉样-β聚集和细胞毒性的剂量依赖性调制器。在这最近的工作中,我们试图进一步在治疗相关的AD转基因小鼠模型中评价这种新型调制器。使APPSwDI/NOS2-/- 小鼠口服BBG三个月以评估其生物相容性,其穿过血脑屏障的渗透性和其在治疗AD症状时的疗效。结果表明,BBG的耐受性良好,没有造成显着的体重变化/不寻常的行为,并能够显著的跨ADAPPSwDI/NOS2-/- 小鼠血脑屏障。免疫组织化学和电子脑切片的显微分析表明,BBG能够显著抑制神经元的损失和减少海马神经元细胞内的APP /β。这是第一个报告1)亮蓝G在AD转基因动物模型对神经元损失的影响,2)口服BBG影响蛋白质构象/聚集病,和3)电镜超微结构分析APPSwDI/NOS2-/- 小鼠的AD病理。
关键词: 阿尔茨海默病,淀粉样-β,血脑屏障,细胞内淀粉样-β,神经元损失,三苯甲烷染料
Current Alzheimer Research
Title:Oral Triphenylmethane Food Dye Analog, Brilliant Blue G, Prevents Neuronal Loss in APPSwDI/NOS2-/- Mouse Model
Volume: 13 Issue: 6
Author(s): Jacob A. Irwin, Alev Erisir, Inchan Kwon
Affiliation:
关键词: 阿尔茨海默病,淀粉样-β,血脑屏障,细胞内淀粉样-β,神经元损失,三苯甲烷染料
摘要: Reducing amyloid-β (Aβ) accumulation is a promising strategy for developing Alzheimer’s Disease (AD) therapeutics. We recently reported that a triphenylmethane food dye analog, Brilliant Blue G (BBG), is a dose-dependent modulator of in vitro amyloid-β aggregation and cytotoxicity in cell-based assays. Following up on this recent work, we sought to further evaluate this novel modulator in a therapeutically-relevant AD transgenic mouse model. BBG was orally administered to APPSwDI/NOS2-/- mice for three months in order to assess its biocompatibility, its permeability across the blood-brain barrier, and its efficacy at rescuing AD pathology. The results showed that BBG was well-tolerated, caused no significant weight change/unusual behavior, and was able to significantly cross the AD blood-brain barrier in APPSwDI/NOS2-/- mice. Immunohistochemical and electron microscopic analysis of the brain sections revealed that BBG was able to significantly prevent neuronal loss and reduce intracellular APP/Aβ in hippocampal neurons. This is the first report of 1) the effect of Brilliant Blue G on neuronal loss in a transgenic animal model of AD, 2) oral administration of BBG to affect a protein conformation/aggregation disease, and 3) electron microscopic ultrastructural analysis of AD pathology in APPSwDI/NOS2-/- mice.
Export Options
About this article
Cite this article as:
Jacob A. Irwin, Alev Erisir, Inchan Kwon , Oral Triphenylmethane Food Dye Analog, Brilliant Blue G, Prevents Neuronal Loss in APPSwDI/NOS2-/- Mouse Model, Current Alzheimer Research 2016; 13 (6) . https://dx.doi.org/10.2174/1567205013666160208142456
DOI https://dx.doi.org/10.2174/1567205013666160208142456 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Complex Actions of Statins in Brain and their Relevance for Alzheimer`s Disease Treatment: An Analytical Review
Current Alzheimer Research Chromogranin A and the Endothelial Barrier Function
Current Medicinal Chemistry The Effect of the Antioxidant Drug "U-74389G" on Oophoritis During Ischemia Reperfusion Injury in Rats
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Current Research on Opioid Receptor Function
Current Drug Targets Medicinal Properties of Mangiferin, Structural Features, Derivative Synthesis, Pharmacokinetics and Biological Activities
Mini-Reviews in Medicinal Chemistry Biomedical Advances for Spaceflight Improve Healthcare on Earth
Current Biotechnology Is there a Role for Bevacizumab in Non-Glial Tumors?
Current Drug Targets Brain Slices as Models for Neurodegenerative Disease and Screening Platforms to Identify Novel Therapeutics
Current Neuropharmacology Medical Management of Parkinsons Disease: Focus on Neuroprotection
Current Neuropharmacology The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development
Current Medicinal Chemistry Low Molecular Weight Compounds with Transition Metals as Free Radical Scavengers and Novel Therapeutic Agents
Cardiovascular & Hematological Agents in Medicinal Chemistry Understanding the Global Problem of Drug Addiction is a Challenge for IDARS Scientists
Current Neuropharmacology Protective Effects of Melatonin and Mitochondria-targeted Antioxidants Against Oxidative Stress: A Review
Current Medicinal Chemistry Antioxidants as a Potential Preventive and Therapeutic Strategy for Cadmium
Current Drug Targets Microglia Phenotype Diversity
CNS & Neurological Disorders - Drug Targets Oxidation of Potassium Channels in Neurodegenerative Diseases: A Mini- Review
CNS & Neurological Disorders - Drug Targets Recent Advances in the Comprehension and the Management of Perioperative Systemic Host Response During Cardiopulmonary Bypass
Recent Patents on Cardiovascular Drug Discovery Fuzzy Bee Segmentation-Meta-Heuristic Approach for the Medical Image Segmentation Problem
Current Signal Transduction Therapy Antioxidant Therapy for Prevention of Inflammation, Ischemic Reperfusion Injuries and Allograft Rejection
Cardiovascular & Hematological Agents in Medicinal Chemistry Current Overview of Inorganic Nanoparticles for the Treatment of Central Nervous System (CNS) Diseases
Current Nanomaterials